Skip to Content

My Cancer Genome

My Cancer Genome is a precision cancer medicine knowledge resource for physicians, patients, caregivers and researchers.

VICC toll-free number 1-877-936-8422

Center for Cancer Targeted Therapies

Recent advances in tumor genetics and drug development have led to a wealth of anticancer targeted therapies. These drugs mainly act against tumors with one or more specific alterations in their DNA.

However, for the majority targeted therapies in development – and their combinations with current standard therapies – there are still no approved diagnostic tools to determine which patients are most likely to benefit from or be resistant to these novel agents or drug combinations.

Drugs are often developed at doses that do not ‘hit’ their molecular target in the cancer. Patient enrollment, cost, and inadequate research infrastructure for deep molecular analyses contribute to this problem. This leads to a drug approval process that is too prolonged, generally inefficient, expensive, and/or of modest incremental benefit.

Vanderbilt-Ingram Cancer Center has recognized the need, opportunity, and responsibility to integrate investigators and resources into an interdisciplinary center that can address the complexities and challenges of modern clinical development of anticancer drugs. The Center for Cancer Targeted Therapies (C2T2) integrates a phase I-Ib/early clinical trials program, a precision cancer medicine infrastructure with expertise on tumor tissue-based state-of-the-art molecular methods, and a core resource with novel non-invasive functional imaging methods.


The mission of the Center for Cancer Targeted Therapies (C2T2) at Vanderbilt-Ingram Cancer Center is to advance the development of new, targeted anti-cancer drugs. To address the challenges involved in this process, the C2T2 brings together our early phase clinical trials program, precision cancer medicine initiatives, and non-invasive imaging core.

By expanding clinical trials at Vanderbilt-Ingram, the C2T2 will contribute to faster approval of new targeted drugs and combination therapies for cancer patients.

  • To expand the Vanderbilt-Ingram Cancer Center's portfolio of early phase trials with new drugs and combinations
  • To promote, facilitate and increase patient enrollment into these trials
  • To educate patients, advocates and providers on precision medicine and promote its incorporation into cancer care
  • To become the premier center of excellence for drug development in our region
  • To contribute to the acceleration of new drug approvals (by the FDA) for patients with cancer
Related Links